ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

TNM Classification of Malignant Tumours

1987 • 16,209 citations

BMDP Statistical Software 1981.

1984 • 5,347 citations

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

1989 • 1,494 citations

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1995 • 1,464 citations

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

1999 • 983 citations

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

1994 • 940 citations

Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

1998 • 857 citations

Carcinoma of the Prostate

1991 • 755 citations

TNM: CLASSIFICATION OF MALIGNANT TUMOURS

1969 • 753 citations

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.

1997 • 719 citations

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

1999 • 606 citations

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

1999 • 592 citations

Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients

1995 • 276 citations

MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS

1995 • 234 citations

Identification of bone marrow micrometastases in patients with prostate cancer

1994 • 159 citations

Improved technique for analysis of formalin‐fixed, paraffin‐embedded tumors by fluorescence in situ hybridization

1994 • 136 citations

Carcinoma of the prostate. Hormonal therapy

1987 • 103 citations

PROSTATE REBIOPSY IS A POOR SURROGATE OF TREATMENT EFFICACY IN LOCALIZED PROSTATE CANCER

1998 • 79 citations

Benefits of Combination Therapy with Flutamide in Patients Relapsing after Castration

1988 • 72 citations

Androgen Receptor Gene Amplification in a Recurrent Prostate Cancer after Monotherapy with the Nonsteroidal Potent Antiandrogen Casodex (Bicalutamide) with a Subsequent Favorable Response to Maximal Androgen Blockade

1997 • 70 citations

PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer

1999 • 67 citations

DETECTION OF CIRCULATING PROSTATE SPECIFIC ANTIGEN EXPRESSING PROSTATIC CELLS IN THE BONE MARROW OF RADICAL PROSTATECTOMY PATIENTS BY SENSITIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION

1999 • 41 citations

Hormone refractory disease

1995 • 33 citations

Combined androgen blockade for the treatment of metastatic cancer of the prostate

1996 • 29 citations

Adrenal androgen blockade in relapsed prostate cancer

1985 • 27 citations

Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer

1986 • 24 citations

Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experience

1987 • 6 citations